Literature DB >> 6687892

Intrathyroidal concentrations of methimazole in patients with Graves' disease.

R Jansson, P A Dahlberg, H Johansson, B Lindström.   

Abstract

A sensitive gas chromatographic-mass spectrometric method enabled us to study intrathyroidal concentrations of methimazole in 20 euthyroid patients with Graves' disease on treatment with carbimazole and T4. There was no difference between patients receiving a final dose of carbimazole (10 mg), known to be totally bioactivated to methimazole (6.1 mg), 3-6 h before thyroid excision (518 ng/g thyroid tissue +/- 90 SEM) and patients who received the same dose 17-20 h before excision (727 ng/g thyroid tissue +/- 157 SEM), indicating a slow intrathyroidal turnover of the drug. On the other hand, the serum concentrations were much higher in the first group (102 ng/ml +/- 5 SEM vs. 16 ng/ml +/- 3 SEM), reflecting a short plasma half-life of the drug. The intrathyroidal concentrations of methimazole ranged from 230-1895 ng/g among individual glands but were similar in pieces from different parts of a single gland. These methimazole concentrations are lower than the concentrations reported by others to have an immunosuppressive action on lymphocytes in vitro.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6687892     DOI: 10.1210/jcem-57-1-129

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.

Authors:  J H Romaldini; M C Werner; H F Rodrigues; V L Teixeira; R S Werner; C S Farah; N Bromberg
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

2.  Are antithyroid drugs immunosuppressive?

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-31

3.  Are antithyroid drugs immunosuppressive?

Authors:  P Kendall-Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

4.  The effect of methimazole on the immune system is unlikely to operate directly on T lymphocytes.

Authors:  M Bagnasco; D Venuti; G Ciprandi; G Pesce; F Paolieri; G W Canonica
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

5.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

6.  Thyroid peroxidase forms thionamide-sensitive homodimers: relevance for immunomodulation of thyroid autoimmunity.

Authors:  David O McDonald; Simon H S Pearce
Journal:  J Mol Med (Berl)       Date:  2009-08-08       Impact factor: 4.599

7.  Current and emerging treatment options for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Shamasunder Acharya
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

8.  Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.

Authors:  M Messina; P Milani; L Gentile; A Monaco; C Brossa; M Porta; F Camanni
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

9.  Pharmacokinetics of methimazole in humans.

Authors:  J H Hengstmann; H Hohn
Journal:  Klin Wochenschr       Date:  1985-12-02

10.  Inhibition of the receptor for interleukin-2 induced by carbimazole: relevance for the therapy of autoimmune thyroid disease.

Authors:  A Signore; P Pozzilli; U Di Mario; M Sensi; P Beales; D Andreani
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.